Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1981 1
1982 1
1983 1
1984 3
1985 3
1986 4
1987 4
1988 3
1989 6
1990 3
1991 2
1992 1
1995 1
1996 4
1997 2
1998 3
1999 4
2001 1
2002 4
2003 2
2004 2
2005 7
2006 6
2007 5
2008 14
2009 6
2010 9
2011 5
2012 6
2013 7
2014 12
2015 6
2016 14
2017 8
2018 4
2019 1
2020 4
2021 3
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

159 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome.
Bittner VA, Szarek M, Aylward PE, Bhatt DL, Diaz R, Edelberg JM, Fras Z, Goodman SG, Halvorsen S, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Moriarty PM, Moryusef A, Pordy R, Roe MT, Sinnaeve P, Tsimikas S, Vogel R, White HD, Zahger D, Zeiher AM, Steg PG, Schwartz GG; ODYSSEY OUTCOMES Committees and Investigators. Bittner VA, et al. Among authors: aylward pe. J Am Coll Cardiol. 2020 Jan 21;75(2):133-144. doi: 10.1016/j.jacc.2019.10.057. J Am Coll Cardiol. 2020. PMID: 31948641 Free article. Clinical Trial.
Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction.
Gibson CM, Kastelein JJP, Phillips AT, Aylward PE, Yee MK, Tendera M, Nicholls SJ, Pocock S, Goodman SG, Alexander JH, Lincoff AM, Bode C, Duffy D, Heise M, Berman G, Mears SJ, Tricoci P, Deckelbaum LI, Steg PG, Ridker P, Mehran R. Gibson CM, et al. Among authors: aylward pe. Am Heart J. 2021 Jan;231:121-127. doi: 10.1016/j.ahj.2020.10.052. Epub 2020 Oct 13. Am Heart J. 2021. PMID: 33065120 Free article.
Tackling cardiometabolic risk in the Asia Pacific region.
Li JJ, Yeo KK, Tan K, Ako J, Krittayaphong R, Tan RS, Aylward PE, Lam CP, Baek SH, Dalal J, Fong A, Li YH, O'Brien RC, Koh SYN, Scherer DJ, Tada H, Kang V, Butters J, Nicholls SJ. Li JJ, et al. Among authors: aylward pe. Am J Prev Cardiol. 2020 Nov 8;4:100096. doi: 10.1016/j.ajpc.2020.100096. eCollection 2020 Dec. Am J Prev Cardiol. 2020. PMID: 34327472 Free PMC article. Review.
Polygenic Risk Scores for Atherosclerotic Cardiovascular Disease in the Asia-Pacific Region.
Tada H, Yeo KK, Li JJ, Tan K, Ako J, Krittayaphong R, San Tan R, Aylward PE, Lam CSP, Baek SH, Dalal J, Fong A, Li YH, O'Brien RC, Natalie Koh SY, Scherer DJ, Kang V, Nelson AJ, Butters J, Nicholls SJ. Tada H, et al. Among authors: aylward pe. JACC Asia. 2021 Dec 21;1(3):294-302. doi: 10.1016/j.jacasi.2021.08.008. eCollection 2021 Dec. JACC Asia. 2021. PMID: 36341217 Free PMC article. Review.
Statin intolerance: an updated, narrative review mainly focusing on muscle adverse effects.
Li JJ, Liu HH, Wu NQ, Yeo KK, Tan K, Ako J, Krittayaphong R, Tan RS, Aylward PE, Baek SH, Dalal J, Fong AYY, Li YH, O'Brien RC, Lim TSE, Koh SYN, Scherer DJ, Tada H, Kang V, Butters J, Nicholls SJ. Li JJ, et al. Among authors: aylward pe. Expert Opin Drug Metab Toxicol. 2020 Sep;16(9):837-851. doi: 10.1080/17425255.2020.1802426. Epub 2020 Aug 11. Expert Opin Drug Metab Toxicol. 2020. PMID: 32729743 Review.
159 results